Charles Schwab Investment Management Inc. Has $278.56 Million Position in Edwards Lifesciences Co. (NYSE:EW)

Charles Schwab Investment Management Inc. lifted its holdings in Edwards Lifesciences Co. (NYSE:EW) by 2.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,762,761 shares of the medical research company’s stock after purchasing an additional 103,659 shares during the period. Charles Schwab Investment Management Inc. owned 0.64% of Edwards Lifesciences worth $278,557,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in EW. FSA Wealth Management LLC bought a new position in Edwards Lifesciences in the 3rd quarter worth approximately $30,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of Edwards Lifesciences in the fourth quarter worth $30,000. Prospera Private Wealth LLC bought a new position in Edwards Lifesciences during the third quarter worth $32,000. Avior Wealth Management LLC raised its stake in Edwards Lifesciences by 138.7% during the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 308 shares during the last quarter. Finally, Roble Belko & Company Inc bought a new stake in Edwards Lifesciences in the 4th quarter valued at $46,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock opened at $72.89 on Thursday. The business’s fifty day moving average is $72.45 and its two-hundred day moving average is $70.35. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The firm has a market cap of $42.99 billion, a P/E ratio of 10.46, a P/E/G ratio of 4.82 and a beta of 1.10. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Equities research analysts forecast that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently issued reports on EW. Evercore ISI dropped their price objective on shares of Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating on the stock in a report on Wednesday, February 12th. Barclays boosted their price target on Edwards Lifesciences from $88.00 to $90.00 and gave the company an “overweight” rating in a research note on Thursday, February 13th. Stifel Nicolaus upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and raised their price objective for the stock from $75.00 to $90.00 in a research report on Thursday, January 30th. Truist Financial restated a “hold” rating and set a $78.00 price objective (up from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. Finally, Morgan Stanley upped their target price on Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $79.95.

Insider Activity at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 2,500 shares of Edwards Lifesciences stock in a transaction on Monday, December 16th. The stock was sold at an average price of $74.08, for a total transaction of $185,200.00. Following the completion of the sale, the vice president now directly owns 23,189 shares of the company’s stock, valued at $1,717,841.12. The trade was a 9.73 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Scott B. Ullem sold 11,250 shares of the company’s stock in a transaction dated Friday, February 28th. The shares were sold at an average price of $70.78, for a total value of $796,275.00. Following the completion of the sale, the chief financial officer now owns 30,387 shares of the company’s stock, valued at $2,150,791.86. This represents a 27.02 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 37,739 shares of company stock worth $2,799,104 over the last 90 days. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.